The HIV envelope (Env) protein gp120 is protected from antibody recognition by a dense glycan shield. However, several of the recently identified PGT broadly neutralizing antibodies appear to interact directly with the HIV glycan coat. Crystal structures of antigen-binding fragments (Fabs) PGT 127 and 128 with Man9 at 1.65 and 1.29 angstrom resolution, respectively, and glycan binding data delineate a specific high mannose-binding site. Fab PGT 128 complexed with a fully glycosylated gp120 outer domain at 3.25 angstroms reveals that the antibody penetrates the glycan shield and recognizes two conserved glycans as well as a short β-strand segment of the gp120 V3 loop, accounting for its high binding affinity and broad specificify. Furthermor...
Broadly neutralizing antibodies (bNAbs) to HIV-1 envelope glycoprotein (Env) can prevent infection i...
Broadly neutralizing antibodies (bNAbs) against HIV-1 envelope (Env) inform vaccine design and are p...
Broadly neutralizing antibodies (bNAbs) isolated from HIV-1-infected individuals inform HIV-1 vaccin...
A substantial proportion of the broadly neutralizing antibodies (bnAbs) identified in certain HIV-in...
<div><p>New broad and potent neutralizing HIV-1 antibodies have recently been described that are lar...
A substantial proportion of the broadly neutralizing antibodies (bnAbs) identified in certain HIV-in...
New broad and potent neutralizing HIV-1 antibodies have recently been described that are largely dep...
Broadly neutralizing antibodies have been isolated that bind the glycan shield of the HIV-1 envelope...
Broadly neutralizing antibodies have been isolated that bind the glycan shield of the HIV-1 envelope...
Broadly neutralizing antibodies have been isolated that bind the glycan shield of the HIV-1 envelope...
Broadly neutralizing HIV antibodies (bNAbs) can recognize carbohydrate-dependent epitopes on gp120. ...
Broadly neutralizing antibodies (bNAbs) isolated from HIV-1-infected individuals inform HIV-1 vaccin...
SummaryThe HIV envelope glycoprotein (Env) is densely covered with self-glycans that should help shi...
Broadly neutralizing antibodies (bNAbs) isolated from HIV-1-infected individuals inform HIV-1 vaccin...
Broadly neutralizing antibodies (bNAbs) isolated from HIV-1-infected individuals inform HIV-1 vaccin...
Broadly neutralizing antibodies (bNAbs) to HIV-1 envelope glycoprotein (Env) can prevent infection i...
Broadly neutralizing antibodies (bNAbs) against HIV-1 envelope (Env) inform vaccine design and are p...
Broadly neutralizing antibodies (bNAbs) isolated from HIV-1-infected individuals inform HIV-1 vaccin...
A substantial proportion of the broadly neutralizing antibodies (bnAbs) identified in certain HIV-in...
<div><p>New broad and potent neutralizing HIV-1 antibodies have recently been described that are lar...
A substantial proportion of the broadly neutralizing antibodies (bnAbs) identified in certain HIV-in...
New broad and potent neutralizing HIV-1 antibodies have recently been described that are largely dep...
Broadly neutralizing antibodies have been isolated that bind the glycan shield of the HIV-1 envelope...
Broadly neutralizing antibodies have been isolated that bind the glycan shield of the HIV-1 envelope...
Broadly neutralizing antibodies have been isolated that bind the glycan shield of the HIV-1 envelope...
Broadly neutralizing HIV antibodies (bNAbs) can recognize carbohydrate-dependent epitopes on gp120. ...
Broadly neutralizing antibodies (bNAbs) isolated from HIV-1-infected individuals inform HIV-1 vaccin...
SummaryThe HIV envelope glycoprotein (Env) is densely covered with self-glycans that should help shi...
Broadly neutralizing antibodies (bNAbs) isolated from HIV-1-infected individuals inform HIV-1 vaccin...
Broadly neutralizing antibodies (bNAbs) isolated from HIV-1-infected individuals inform HIV-1 vaccin...
Broadly neutralizing antibodies (bNAbs) to HIV-1 envelope glycoprotein (Env) can prevent infection i...
Broadly neutralizing antibodies (bNAbs) against HIV-1 envelope (Env) inform vaccine design and are p...
Broadly neutralizing antibodies (bNAbs) isolated from HIV-1-infected individuals inform HIV-1 vaccin...